Michael Andrew Chambers
Known title: DirectorCIK: 0001932527
Michael Andrew Chambers's purchase track record
How the stock did after each of Michael Andrew Chambers's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since August 19, 2022
Stock higher 6 months later
75%
3 months: 50%
Median 6-month return
+17.8%
3 months: -8.9%
Beat the S&P 500
75%
median +13.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2024 | SRPT | $4.96M | -21.7% | -19.1% | +10.1% |
| 8/10/2023 | SRPT | $7.35M | -25.3% | +20.2% | +11.8% |
| 9/14/2022 | SRPT | $5.96M | +17.4% | +35.2% | -1.4% |
| 8/19/2022 | SRPT | $5.00M | +3.8% | +15.5% | -3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SRPT | ▲ Buy | Grant | 16,875 | — | 6/4/2026 | View on chart |
| SRPT | ▲ Buy | Grant | 2,383 | — | 3/10/2025 | View on chart |
| SRPT | ▲ Buy | Open Market | 13,106 | $1.7M | 8/16/2024 | View on chart |
| SRPT | ▲ Buy | Open Market | 18,284 | $2.5M | 8/16/2024 | View on chart |
| SRPT | ▲ Buy | Open Market | 5,648 | $761K | 8/16/2024 | View on chart |
| SRPT | ▲ Buy | Grant | 1,846 | $0 | 3/1/2024 | View on chart |
| SRPT | ▲ Buy | Open Market | 5,947 | $649K | 8/14/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 4,032 | $443K | 8/14/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 23,686 | $2.6M | 8/11/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 2,206 | $231K | 8/10/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 1,091 | $116K | 8/10/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 31,570 | $3.4M | 8/10/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 1,523 | $0 | 3/6/2023 | View on chart |
| SRPT | ▲ Buy | Open Market | 6,250 | $657K | 9/14/2022 | View on chart |
| SRPT | ▲ Buy | Open Market | 30,106 | $3.2M | 9/14/2022 | View on chart |
| SRPT | ▲ Buy | Open Market | 20,744 | $2.2M | 9/14/2022 | View on chart |
| SRPT | ▲ Buy | Open Market | 6,060 | $659K | 8/19/2022 | View on chart |
| SRPT | ▲ Buy | Open Market | 40,110 | $4.3M | 8/19/2022 | View on chart |
| SRPT | ▲ Buy | Grant | 4,908 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.